News

Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum

WALTHAM, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming…

10 months ago

ProMIS Neurosciences to Participate in the 37th Annual Roth Conference

CAMBRIDGE, Massachusetts, March 11, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the…

10 months ago

Bioventus Announces Fourth Quarter and Full Year 2024 Financial Results

Accelerated fourth quarter sales growth to 13.5%Fourth quarter gross margin expanded 310 bps and adjusted gross margin* expanded 230 bpsFourth…

10 months ago

Aurora Spine to Attend the American Academy of Orthopaedic Surgeons Annual Meeting

Carlsbad, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV:ASG) (OTCQB: ASAPF), a designer…

10 months ago

The Joint Corp. Names SVP Development

Highly accomplished franchise development leader with over 20 years of experience to lead growth SCOTTSDALE, Ariz., March 11, 2025 (GLOBE…

10 months ago

Tonix Pharmaceuticals to Present at the Zacks SCR Life Sciences Virtual Investor Forum on March 13th

CHATHAM, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biopharmaceutical company with marketed…

10 months ago

Tilray Medical Launches Tilray Craft: Introducing High THC, High Terpene Genetics to the German Medical Cannabis Market

NEUMÜNSTER, Germany, March 11, 2025 (GLOBE NEWSWIRE) -- Tilray Medical (“Tilray”), a division of Tilray Brands, Inc. (NASDAQ: TLRY and…

10 months ago

Paw-litics Heats Up on the Hill: Cutest Pets on Parliament Hill Contest Returns

TORONTO, March 11, 2025 (GLOBE NEWSWIRE) -- The Canadian Animal Health Institute (CAHI) is excited to launch the 3rd Annual…

10 months ago

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

– Full enrollment in cutaneous melanoma dose-expansion arms of Phase 1/1b clinical trial evaluating WTX-124 as monotherapy and in combination with…

10 months ago